Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 10/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283254 | 0.79 | HRH3 (0.48) | PLA2G2CEPHX1 | |
| SCHEMBL288502 | 0.79 | HRH3 (0.48) | PLA2G2CEPHX1 | |
| SCHEMBL26626453 | 0.79 | HRH3 (0.48) | PLA2G2CEPHX1 | |
| SCHEMBL5199721 | 0.78 | SMN1; SMN2 (0.40) | EPHX1ACHE | |
| SCHEMBL7447157 | 0.78 | FOLH1 (0.51) | — | |
| SCHEMBL16124669 | 0.77 | NOD1 (0.51) | PLA2G2CEPHX1EPHX2 | |
| SCHEMBL10036530 | 0.75 | NOD1 (0.53) | PLA2G2CEPHX1EPHX2 | |
| SCHEMBL7006306 | 0.75 | KMT2A (0.49) | PLA2G2CEPHX2 | |
| SCHEMBL6168369 | 0.75 | KMT2A (0.49) | PLA2G2CEPHX2 | |
| SCHEMBL4631032 | 0.75 | EPHX1 (0.42) | PLA2G2CEPHX1EPHX2ACHECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |